Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5436 participants.

Also called NCT06523959

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 5,436 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06523959
  • EU CT 2023-508147-43-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Finland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06523959. Randomized; no masking; primary purpose treatment. Start 2024-06-06 (actual); primary completion 2028-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial
Acronym
ARTS
Condition
Venous Thromboembolism
Condition
Bleeding
Intervention (Drug)
Apixaban 2.5 MG
Lead sponsor
Clinical Urology and Epidemiology Working Group (class: other government)
Collaborator
Helsinki University Central Hospital (class: other)
Collaborator
University of Helsinki (class: other)
Collaborator
University College, London (class: other)
Collaborator
Population Health Research Institute (class: other)
Collaborator
Tabriz University of Medical Sciences (class: other)
Collaborator
Tampere University Hospital (class: other)
Collaborator
Turku University Hospital (class: other government)
Collaborator
Oulu University Hospital (class: other)
Collaborator
North Karelia Central Hospital (class: other)
Collaborator
Albany Medical College (class: other)
Collaborator
PaijatHame Central Hospital (class: other)

Record details

Record id
cardio:ct-nct06523959
Content hash
837eb9d7435b50e78b40c978ffdabb5c8b5befdf44960054096e020c9f873c33